Effect of apigenin on the osteoporosis in ovariectomized rats and its dose
10.3969/j.issn.2095-4344.1905
- Author:
Lijin LAI
1
Author Information
1. People’s Hospital of Longhua
- Publication Type:Journal Article
- Keywords:
Alkaline phosphatase;
Apigenin;
Estrogen;
Osteoporosis;
Ovariectomized rats
- From:
Chinese Journal of Tissue Engineering Research
2020;24(2):171-175
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Apigenin has been shown to hold the effects of antivirus, anti-inflammation, anti-oxidation and tranquilizer and sedative. OBJECTIVE: To study the effect of different doses of apigenin on osteoporosis in rats and to explore the underlying mechanism. METHODS: The study was approved by the Laboratory Animal Ethical Committee of Southern Medical University. Forty-two adult male Sprague-Dawley rats were selected, and the rat models of osteoporosis were established by ovariectomy. The rats were divided into seven groups (n=6/group): The sham operation group, the control group, the positive control group, and the 20, 40, and 60, and the 80 mg/kg apigenin groups according to the dose of apigenin. The sham operation group did not receive the removal of the ovaries. The positive control group was supplemented with diethylstilbestrol (0.02 mg/kg), vitamin D and calcium daily. The control group was given the subcutaneous injection of same volume of purified water. The apigenin groups were given the subcutaneous injection of various doses of apigenin, respectively, once daily, for 8 weeks. The femoral bone mineral density and serum levels of calcium, phosphorus, bone alkaline phosphatase, amino-terminal propeptide of type I procollagen, C-terminal telopeptide of type I collagen were measured at 4 and 8 weeks after intervention, respectively. RESULTS AND CONCLUSION: (1) Compared with the control group, when the dose of apigenin was 40, 60 and 80 mg/kg, the bone mineral density, and serum levels of calcium and phosphorus were increased significantly at 4 and 8 weeks (P < 0.05), and the levels of amino-terminal propeptide of type I procollagen, C-terminal telopeptide of type I collagen and bone alkaline phosphatase were decreased significantly (P < 0.05). (2) Compared with the positive control group, when the dose of apigenin was 60 and 80 mg/kg, the bone mineral density, serum levels of calcium and phosphorus, the levels of amino-terminal propeptide of type I procollagen, C-terminal telopeptide of type I collagen and bone alkaline phosphatase showed no significant difference at 4 and 8 weeks (P > 0.05). When the dose of apigenin was 20 and 40 mg/kg, compared with the positive control group, the bone mineral density, and serum levels of calcium and phosphorus were decreased significantly at 4 and 8 weeks (P < 0.05), and the levels of amino-terminal propeptide of type I procollagen, C-terminal telopeptide of type I collagen and bone alkaline phosphatase were increased significantly (P < 0.05). (3) Compared with the sham operation group, in the control group, the bone mineral density, and serum levels of calcium and phosphorus were decreased significantly at 4 and 8 weeks (P < 0.05), and the levels of amino-terminal propeptide of type I procollagen, C-terminal telopeptide of type I collagen and bone alkaline phosphatase were increased significantly (P < 0.05). (4) These results suggest that it is indeed effective to establish a rat osteoporosis model by ovariectomy. The therapeutic effect of apigenin on osteoporosis is dose-related, and a certain dose of apigenin has an anti-osteoporosis effect.
